RMB. my take is this . 1) Its always a positive when the CMO and CFO make open market buys . CMO obviously likes the medical implications and CFO sees the value that a larger Co might see in the DME data 2) Market was initially disappointed that there was no signal in improvement of BCVA ( visual Acuity ) . Co ...especially their Stanford KOL argued the trial was to short to see that but the necessary signs ...improvement in CST ( reduced retinal thickening ) were seen and eventually improvement in BCVA would follow ( 6-12 mths later ) . 3) Co does not have the funds to run a large 12 mth trial ....so the spec is whether or not a BP might buy rights to their DME drug or partner in its development. . CFO is betting that a larger Co will make an offer for the drug / DME indication . 4) The potential in the DME drug is that it is expected to slow loss of vision delaying the need for the Eyelea eye injections ( usually every 2 mths )
Stock will probably be volatile JMO No investment advice etc etc FYI. AMRN mgt says UK decision on buyback this Qt . UK law states Co must make decision public within 8 days of receiving decision ( IIRC )
News 
Market Data 
Discover 
